Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Eleda in connection with acquisition of JVAB
Mandate

Vinge advises Eleda in connection with acquisition of JVAB

May 09, 2020 M&A EU, Competition and Regulatory Employment and Benefits Real Estate and Construction

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Järfälla VA- & Byggentreprenad AB (“JVAB”).

JVAB is focusing on civil engineering and transmission infrastructure in the Stockholm region. JVAB has around 150 employees and sales of approximately SEK 0.7 billion in 2019. The majority of JVAB is owned by the founding family, who will reinvest a significant portion in the combined Group. JVAB strengthens Eleda’s geographical coverage in the Stockholm area and has strong expertise in water works. The acquisition is carried out in connection with Altor Fund V’s acquisition of a majority stake in Eleda and Eleda’s acquisition of ONE Nordic.

Vinge’s team consisted of partner Christina Kokko together with associates Michaela Cronemyr, Manne Bergström, Hanna Risberg and Fredric Reissmüller (M&A), Trine Osen Bergqvist, Xandra Ståhlberg and Lisa Malmborg (Competition), Lisa Ullman (Employment), Rebecka Maltenius (Construction) and Nathalie Hughes (VDR assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025